ICON Public (NASDAQ:ICLR) PT Lowered to $285.00

ICON Public (NASDAQ:ICLR) had its price target dropped by research analysts at TD Cowen from $369.00 to $285.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target points to a potential upside of 29.27% from the stock’s previous close.

A number of other equities research analysts also recently commented on the company. JPMorgan Chase & Co. decreased their target price on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a report on Friday. Leerink Partners decreased their price objective on shares of ICON Public from $376.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday. Barclays dropped their price objective on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a report on Friday. Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday. Finally, Robert W. Baird lowered shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price target on the stock. in a report on Thursday. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, ICON Public presently has a consensus rating of “Moderate Buy” and an average price target of $310.45.

ICON Public Stock Down 0.6 %

NASDAQ:ICLR opened at $220.47 on Friday. The company’s 50 day moving average is $297.75 and its two-hundred day moving average is $310.20. The company has a market cap of $18.19 billion, a PE ratio of 25.70, a P/E/G ratio of 1.35 and a beta of 1.22. ICON Public has a twelve month low of $220.01 and a twelve month high of $347.72. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. ICON Public’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 earnings per share. Analysts anticipate that ICON Public will post 14.53 EPS for the current year.

Institutional Investors Weigh In On ICON Public

Institutional investors have recently modified their holdings of the business. Ashton Thomas Private Wealth LLC purchased a new position in ICON Public during the second quarter worth approximately $54,000. ORG Partners LLC acquired a new stake in ICON Public in the 2nd quarter valued at $59,000. Whittier Trust Co. of Nevada Inc. raised its position in ICON Public by 410.8% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock worth $63,000 after acquiring an additional 152 shares during the period. GAMMA Investing LLC lifted its holdings in ICON Public by 50.0% during the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after purchasing an additional 87 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of ICON Public by 17.4% in the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after purchasing an additional 42 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.